Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.

CONCLUSION: There are a number of challenges associated with the use of copanlisib. Infusion-related hypertension and hyperglycemia occur frequently, although they are transient, reversible, and rarely of clinical significance; this report provides guidance as to their management.
PMID: 30584024 [PubMed - as supplied by publisher]

Source: Clinical Lymphoma and Myeloma - November 29, 2018 Category: Cancer & Oncology Authors: Cheson BD, O'Brien S, Ewer MS, Goncalves MD, Farooki A, Lenz G, Yu A, Fisher RI, Zinzani PL, Dreyling M Tags: Clin Lymphoma Myeloma Leuk Source Type: research